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Abstract
Background: Apolipoprotein D (ApoD) is a lipocalin involved in several processes including lipid
transport, but its modulation during human pregnancy was never examined.
Methods: We investigated the changes in the levels of ApoD in the plasma of pregnant women at
the two first trimesters of gestation and at delivery as well as in the placenta and in venous cord
blood. These changes were studied in 151 women classified into 9 groups in relation to their
prepregnancy body mass index (BMI) and gestational weight gain (GWG).
Results: Plasma ApoD levels decrease significantly during normal uncomplicated pregnancy. ApoD
is further decreased in women with excessive GWG and their newborns. In these women, the
ApoD concentration was tightly associated with the lipid parameters. However, the similar ApoD
levels in low cholesterol (LC) and high cholesterol (HC) women suggest that the plasma ApoD
variation is not cholesterol dependant. A tight regulation of both placental ApoD transcription and
protein content is most probably at the basis of the low circulating ApoD concentrations in women
with excessive GWG. After delivery, the plasma ApoD concentrations depended on whether the
mother was breast-feeding or not, lactation favoring a faster return to baseline values.
Conclusion: It is speculated that the decrease in plasma ApoD concentration during pregnancy is
an adaptive response aimed at maintaining fetal lipid homeostasis. The exact mechanism of this
adaptation is not known.
Background
Human pregnancy is associated with profound changes in
the maternal lipid, carbohydrate and protein metabo-
lisms. These changes are aimed at favoring the mainte-
nance of pregnancy, sustaining fetal growth and brain
development, and facilitating parturition [1]. Maternal
metabolism is intimately linked with prepregnancy body
mass index (BMI) and gestational weight gain (GWG),
which greatly influence the outcome of pregnancy [2]. In
association with an unhealthy lifestyle, suboptimal pre-
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pregnancy BMI and GWG also increase the risk of birth
defects and chronic health problems in the children [3].
The maternal lipid metabolism during pregnancy is char-
acterized by progressive increases in plasma cholesterol
and triglyceride levels accompanied by increases in low
density lipoprotein (LDL) and very low density lipopro-
tein (VLDL), leading to maternal hyperlipidemia during
late pregnancy [4]. Cholesterol is essential for optimal
embryonic and fetal development. It is an important com-
ponent of plasma membranes, required for cell prolifera-
tion, differentiation and morphogenesis modulation [5].
It is also used by the placenta for the synthesis of steroid
hormones [6]. Triglycerides are also crucial as they are
used as a source of essential fatty acids for the fetus,
although they do not directly cross the placental barrier
[7].
Plasma lipid metabolism is regulated in part by the spe-
cific apolipoprotein constituents of the various lipopro-
tein classes. The pregnancy induced hyperlipidemia is
accompanied by a rise in the plasma levels of some apol-
ipoproteins, namely ApoA-1, ApoB, ApoC-II and ApoC-
III. Apolipoprotein D (ApoD) is a secreted lipocalin
assigned with many putative functions including lipid
transport. Its macromolecular distribution extends from
VLDL to very high density lipoproteins (VHDL) with a
maximum concentration in high density lipoproteins 3
(HDL3) [8]. It is considered an atypical apolipoprotein as
both its structure and major sites of synthesis differ from
the other apolipoproteins. Indeed, in human, ApoD is
poorly expressed in the liver and intestine while it is
highly expressed in adrenal glands, spleen, kidneys, pan-
creas, placenta, nervous system, lungs, ovaries and testes
[[9], Rassart et al., unpublished results]. Several hydro-
phobic molecules were identified as its potential ligands
including cholesterol [9], bilirubin [10], pregnenolone,
progesterone, estrogens [11,12] and arachidonic acid
[13].
ApoD expression is modulated in many situations (for
review see [14,15]), namely cellular growth and differen-
tiation [16-19], cancer [19,20], nervous system patholo-
gies [21-24] inflammation [25,26] and oxidative stress
[27-29]. ApoD is also involved in gestation and fetus
development. In human, it is up-regulated in the
endometrium during the window of uterine receptivity for
embryonic implantation [30], is highly expressed in pla-
centa [9] and is found in colustrum and milk [31]. Its lev-
els are also increased in fallopian tubes and ovaries of
gestating compared to non-gestating guinea pigs [32] but
are decreased in lactating compared to virgin mouse
mammary gland [33]. During mouse development, ApoD
expression is selectively modulated from embryonic day
8.5 (E8.5) to birth [34] and in brain, its expression coin-
cides with the period of active myelination and synap-
togenesis [35]. The role of ApoD in embryogenesis is not
limited to mammals as it is found in the yolk of the rap-
idly growing chicken oocyte, where it might transport lip-
ids or regulatory molecules such as vitamin A and thyroid
hormones [36,37], and expressed during late chicken
embryogenesis [38].
In spite of the important role of ApoD in lipid transport,
its expression in gestation-related tissues and during fetus
development, and also despite numerous studies on other
apolipoproteins, there is no available information con-
cerning ApoD modulation throughout human pregnancy.
To address this question, we measured ApoD levels in
plasma at each trimester of pregnancy, in cord blood, two
months after delivery and in placenta. We also examined
how ApoD levels are modified by factors affecting lipid
metabolism such as maternal prepregnancy BMI, gesta-
tional weight gain and hypercholesterolemia.
Methods
Population
The women participating in the study were recruited at
their first prenatal visit, before their tenth week of preg-
nancy, at the Clinique Fidès of Montréal (Montréal, QC,
Canada) and at the Saint-Luc Hospital's Perinatology
Service of the Centre Hospitalier de l'Université de Mon-
tréal (CHUM, Montréal, QC, Canada), from 2002-2006.
This study included 151 pregnant women of similar socio-
economic situation. The study was approved by the ethi-
cal committee of CHUM and Université du Québec à
Montréal (Montréal, QC, Canada). All subjects provided
written informed consent. The exclusion criteria were ges-
tational or type 2 diabetes, preeclampsia, hypertension,
consumption of drugs interfering with lipid metabolism
and complications during pregnancy or at delivery. A
group of 5 non-pregnant women of similar age than the
pregnant subjects examined, having a BMI of 20-26 kg/m2
and with plasma biochemistry within the expected nor-
mal ranges was also included.
Population classification
The study population was classified into 9 groups accord-
ing to their prepregnancy BMI, confirmed at their first pre-
natal visit, and GWG. In accordance with Health Canada
recommendations (2002), the normal values for BMI
were established at 20-26 kg/m2. In order to facilitate the
analysis, the normal values for GWG were established at
11-18 kg independently of the BMI [39-41]. The normal
control group was defined as: BMI 20-26 kg/m2, GWG 11-
18 kg. Women with a BMI under 20 or above 26 kg/m2
were designated as low and high BMI, respectively, while
women with a GWG under 11 or above 18 kg were desig-
nated as low and high GWG, respectively. A classification
based on the median plasmatic total cholesterol level at
delivery (6,85 mM) was also established. Women with aReproductive Biology and Endocrinology 2009, 7:92 http://www.rbej.com/content/7/1/92
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cholesterol concentration inferior to 7 mM (n = 38) were
referred to as the low cholesterol group (LC) while
women with a cholesterol concentration superior to 8
mM (n = 29) were considered as the non-pathologic high
cholesterol group (HC) [42-44].
Blood and tissue samples
Blood samples were collected at first (10-17 weeks) and
second (22-28 weeks) trimesters of gestation and at deliv-
ery (36-40 weeks). Newborn blood samples were
retrieved from the umbilical cord (venous cord blood).
Blood samples were also collected two months after par-
turition (postpartum) from lactating and non-lactating
women. The blood samples were centrifuged 15 min at
3,500 × g and plasma samples were kept at -20°C until
analysis. The placentas, from vaginal delivery, were
obtained from the Saint-Luc Hospital of CHUM (Mon-
tréal, QC, Canada) and were immediately immersed in
Dulbecco's Modified Eagle Medium (DMEM) (Sigma,
Oakville, ON, Canada) supplemented with antibiotics
(penicillin, streptomycin and neomycin, Invitrogen, Burl-
ington, ON, Canada) and NaHCO3. After the removal of
the amnion, the chorion and the decidual layer, the pla-
cental tissue was randomly cut in 5 cm2 sections, immedi-
ately frozen in liquid nitrogen and kept at -80°C until
analysis.
Plasma biochemistry
The plasma levels of total cholesterol, LDL-cholesterol,
HDL-cholesterol and triglycerides were individually meas-
ured using the UniCel 36 DX600 Synchron Clinical Sys-
tem (Beckman-Coulter, Mississauga, ON, Canada) at the
Clinical Biochemistry Service of Saint-François d'Assise
Hospital (Québec, QC, Canada). Total plasma fatty acids
were measured by gas phase chromatography. ApoA-1
and ApoB-100 levels were measured by RIA or ELISA
methods at the Centre Hospitalier Universitaire de
Québec (Québec, QC, Canada). ApoD levels were meas-
ured by competitive ELISA using the human ApoD mon-
oclonal antibody 2B9 as previously described [22].
Briefly, microtiter plates were coated with antigen (1 μg
ApoD/ml) overnight at 4°C in 5 mM glycin buffer (pH
9.2). Unreacted sites were blocked with PBS-BSA 1% for 1
h. A mixture containing diluted plasma and 2B9 antibody
in PBS-BSA 1% then replaced the saturation solution.
Bound 2B9 antibody was detected by peroxidase labeled
anti-mouse IgG (KPL, Gaithersburg, MD) and revealed
with ABTS substrate (2,2'-azino-bis(3-ethylbenzthiazo-
line-6-sulphonic acid; KPL). Optical density was meas-
ured at 410 nm. All quantifications were performed in
triplicate.
RNA isolation and quantitative Real-Time PCR (qRT-PCR)
Total RNA was prepared from 25 mg of placental tissue
using the High Pure RNA Tissue Kit (Roche Diagnostics,
Laval, QC, Canada) according to the manufacturer's
instructions. Subsequently, cDNA was obtained by reverse
transcription of total RNA using the Omniscript RT kit
(Qiagen, Mississauga, ON, Canada). The quantification of
ApoD and 18S transcripts were assessed by qRT-PCR using
the LightCycler 480 SYBR Green I Master and the LightCy-
cler 480 instrument and software (Roche Diagnostics).
For each gene, diluted amounts of known templates pro-
vided quantitative standard curves from which cDNA
copy number in clinical samples could be determined.
ApoD transcript expression was then normalized versus
the housekeeping gene 18S. The following primers were
used in qRT-PCR: ApoD forward, 5'-CAT CTT GGG AAG
TGC CCC AA-3'; ApoD reverse, 5'-CCA TCA GCT CTC
AAC TCC TGG TTT-3'; 18S forward, 5'-CGC CGC TAG
AGG TGA AAT TC-3'; 18S reverse, 5'-TTG GCA AAT GCT
TTC GCT C-3'.
Placental ApoD quantification
Placental tissues were rinsed 3-4 times in cold 0,9% NaCl
solution containing a mixture of anti-proteases (Com-
plete protease inhibitors-EDTA free, Roche Diagnostics)
to remove blood from tissue. Placental tissues (1 g) were
then homogenized in 1 ml cold lysis buffer (125 mM Tris-
HCl, pH 8,0, 2 mM CaCl2, 1,4% (v/v) Triton X-100, 2%
Complete protease inhibitors-EDTA free, 1 mM phenyl-
methylsulphonylfluoride) using a Polytron tissue homog-
enizer 3000 (Brinkman, Westbury, NY, USA). The
homogenates were centrifuged at 10,000 × g for 25 min at
4°C. The protein concentration of the supernatant was
determined using the BCA (bicinchoninic acid) assay
(Pierce, Brockville, ON, Canada). Supernatants were kept
at -80°C until analysis. The ApoD levels were measured by
competitive ELISA as described above.
Statistical analyses
Data were expressed as means ± SEM and analyzed with
unpaired Student's t-test or Mann-Whitney U test. Results
were considered significant at p < 0.05. The association
between two variables of the same population was
assessed using Pearson's correlation coefficient. All statis-
tical analyses were performed using Prism 4.0 (GraphPad
Software, San Diego, CA, USA).
Results
Population characteristics
As shown in Additional file 1, the 151 pregnant women
participating to this study were classified into 9 groups
according to their prepregnancy BMI and GWG. It was first
observed that GWG had a greater influence on group char-
acteristics at delivery than BMI. For example, in the high
BMI group, suboptimal GWG, i.e. inferior or superior to
the normal range of 11-18 kg, significantly reduced the
pregnancy duration (Additional file 1). Nevertheless, only
the normal BMI, low GWG group had smaller newbornsReproductive Biology and Endocrinology 2009, 7:92 http://www.rbej.com/content/7/1/92
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(Additional file 2). Suboptimal GWG had an even larger
impact on lipid parameters, mainly in the high BMI but
also in the normal BMI group. Unexpectedly, however,
both low and high GWG resulted in decreased lipid levels
(Additional file 1). These changes however had a low inci-
dence on the newborn lipid parameters (Additional file
2).
Plasma ApoD levels decrease during pregnancy
Plasma ApoD levels were measured in women at each tri-
mester of pregnancy. In the control group (BMI 20-26 kg/
m2, GWG 11-18 kg), plasma ApoD concentration
declined early in pregnancy as its levels were already
reduced by 40% at the first trimester of pregnancy com-
pared to non-pregnant women (Figure 1). ApoD levels
continued to progressively decrease at the second trimes-
ter and until delivery where they reached 30% of the levels
in non-pregnant women (Figure 1). A similar significant
decrease of ApoD during gestation was also observed in
our 8 other groups (data not shown). Interestingly, ApoD
levels in the venous cord blood were similar to the levels
in the mother plasma at delivery in all groups, except for
the normal BMI (20-26 kg/m2), low GWG (< 11 kg) group
where cord blood had inferior ApoD levels than the
mother's blood (Figure 1 and Table 1). In spite of this, by
using the Pearson's correlation coefficient, no correlation
was found between ApoD plasma levels in the mother and
the venous cord blood (Table 2 and Additional file 3).
Influence of prepregnancy BMI and GWG on plasma ApoD 
levels
Maternal prepregnancy BMI did not present an impact on
plasma ApoD levels at delivery (Table 1). However, a
GWG superior to 18 kg caused a decrease in maternal
ApoD levels in the normal and low BMI groups but not in
the high BMI group (Table 1). Similarly, GWG but not
BMI also affected venous cord blood ApoD concentration.
Newborns from mothers having a GWG superior to 18 kg
had lower cord blood ApoD levels than newborns from
the other groups (Table 1).
Association between plasma ApoD levels and pregnancy 
parameters
The correlation between ApoD concentration at delivery
and the other pregnancy-related parameters was explored
using Pearson's correlation coefficient. In the control
group, ApoD levels correlated only with total-cholesterol,
in a positive manner (Additional file 3). In the other
groups, ApoD correlations were different and specific to
each group (Additional file 3). Then, since only GWG had
an impact on ApoD values (Table 1), we created 3 new
groups containing all women with similar GWG, regard-
less of their BMI (Table 2). In women with low GWG,
ApoD values were directly correlated with GWG and
inversely correlated with the newborn weight. Moreover,
in women with normal GWG, ApoD was inversely corre-
lated with ApoA-I. In contrast, in women with high GWG,
which present lower ApoD levels, ApoD was correlated
with most of the parameters. ApoD was strongly nega-
tively correlated with most of the lipid parameters except
triglycerides with which ApoD was directly correlated.
ApoD was also negatively correlated with gestational age,
GWG and newborn height and directly correlated with
mother's age and BMI (Table 2). However, although many
of the lipid parameters in women with high GWG are sig-
nificantly different from the normal GWG group, all new-
borns displayed similar lipid parameters independently of
maternal GWG (data not shown).
Table 1: Plasma ApoD (mg/L) in the mother at delivery and in the cord blood.
MOTHER
BMI (kg/m2)
GWG (kg) < 20 20-26 > 26
< 11 76.08 ± 31.36 (n = 9) 87.84 ± 21.94 (n = 28) 64.86 ± 21.54 (n = 20)
11-18 59.30 ± 16.65 (n = 14) 61.69 ± 10.93 (n = 48) 54.44 ± 11.30 (n = 18)
> 18 25.99 ± 14.02 (n = 4) * † 27.45 ± 9.10 (n = 6) * † 46.44 ± 20.96 (n = 4)
CORD BLOOD
BMI (kg/m2)
GWG (kg) < 20 20-26 > 26
< 11 60.35 ± 21.12 (n = 9) 43.48 ± 8.73 (n = 28) # 67.28 ± 17.20 (n = 20)
11-18 64.61 ± 22.20 (n = 14) 56.63 ± 8.96 (n = 48) 85.06 ± 70.11 (n = 18)
> 18 20.26 ± 8.56 (n = 4) * † 36.98 ± 13.00 (n = 6) * 17.25 ± 6.51 (n = 4) †
Data are organized according to maternal weight gain during pregnancy (GWG) and body mass index (BMI) at first trimester. Data are expressed as 
mean ± SEM. * Groups statistically different (p < 0.01) from the normal GWG group (11-18 kg) of the same BMI. † Groups statistically different (p 
< 0.01) from the low GWG group (< 11 kg) of the same BMI. A difference between mother and cord blood of the corresponding group (p < 0.001) 
is indicated by #. All groups presenting differences are in bold characters.Reproductive Biology and Endocrinology 2009, 7:92 http://www.rbej.com/content/7/1/92
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ApoD and cholesterol
To verify if the low ApoD level in women with excessive
GWG was attributable to their lower cholesterol levels
(Additional file 1), and because of the correlation
between plasma ApoD and cholesterol levels in the con-
trol group (Additional file 3), we compared the ApoD lev-
els between low cholesterol (LC) and high cholesterol
(HC) women (Table 3). The HC group had higher total
and LDL-cholesterol, triglycerides, ApoA-I and ApoB-100
levels but lower GWG (Table 3). However, both groups
displayed similar ApoD levels. The 2 groups were also dif-
ferent from the control group described in Additional file
1. As expected, the LC group had lower while the HC
group had higher levels of total cholesterol, LDL-choles-
terol and ApoB-100. In this aspect, the LC group was sim-
ilar to the high GWG groups (Additional files 1 and 3).
The HC group also showed lower GWG and higher triglyc-
erides levels than the control group (Additional files 1 and
3). In spite of this, all newborns displayed similar lipid
parameters independently of maternal cholesterol levels
(data not shown).
The cholesterol level greatly affected the association of
ApoD with maternal and newborn characteristics, ApoD
being more associated with pregnancy-related characteris-
tics in LC than in HC women (Table 3). These associations
differed from the ones described for the control group
(Additional file 3) but showed similarities to those in high
GWG groups (Table 2).
ApoD in placenta
Because of the high levels of ApoD mRNA in human pla-
centa and the importance of this tissue in fetal develop-
ment, we examined placental ApoD transcript and protein
content in relation to maternal BMI and GWG. Besides its
influence on plasma ApoD levels (Table 1), maternal
GWG also affected placental ApoD transcription (Figure
2A). However, in contrast to plasma, ApoD transcript lev-
els were decreased in both low and high GWG compared
with normal GWG groups. This pattern was mostly
Table 2: Association of maternal plasma ApoD levels with clinical and biochemical characteristics at delivery in relation to GWG.
GWG < 11 kg
n = 57
GWG 11-18 kg
n = 80
GWG > 18 kg
n = 14
Mean ± SEM r Mean ± SEM r Mean ± SEM r
Mother age (years) 31.70 ± 0.62 ††† 0.098 30.37 ± 0.45 0.085 29.63 ± 1.07 0.241 ***
Gestational age (weeks) 38.96 ± 0.17 ††† -0.065 39.40 ± 0.14 0.137 39.32 ± 0.37 -0.414 ***
BMI (kg/m2) 25.39 ± 0.61 ††† -0.077 23.65 ± 0.37 -0.044 24.37± 1.59 0.232 ***
GWG (kg) 8.08 ± 0.30 ††† 0.303 *** 14.16 ± 0.21 -0.172 22.75 ± 2.56 ††† -0.365 ***
Newborn weight (g) 3256.96 ± 53.01 ††† -0.300 ** 3411.22 ± 48.54 0.126 3407.16 ± 114.40 -0.552
Newborn height (cm) 51.02 ± 0.28 -0.166 51.55 ± 0.22 0.107 52.00 ± 0.54 -0.559 ***
Cord blood ApoD (mg/L) 54.43 ± 8.01 0.169 65.65 ± 9.35 0.135 28.04 ± 7.14 ††† -0.080
Total cholesterol (mM) 6.75 ± 0.21 0.039 7.04 ± 0.15 -0.153 6.25 ± 0.25 ††† -0.563 **
LDL-cholesterol (mM) 3.67 ± 0.17 0.035 3.90 ± 0.14 -0.094 3.28 ± 0.20 ††† -0.724 **
HDL-cholesterol (mM) 1.76 ± 0.06 0.171 1.81 ± 0.05 -0.145 1.61 ± 0.14 †† -0.598 **
Triglycerides (mM) 2.88 ± 0.14 -0.124 2.94 ± 0.10 -0.085 2.95 ± 0.34 0.631 **
Free fatty acids (mmol/L) 0.66 ± 0.05 -0.107 0.65 ± 0.04 -0.175 0.60 ± 0.06 -0.358 **
ApoA-I (g/L) 2.12 ± 0.05 -0.003 2.14 ± 0.04 -0.215 *** 2.04 ± 0.09 -0.554 **
ApoB-100 (mg/L) 1.31 ± 0.05 0.027 1.40 ± 0.04 -0.165 1.27 ± 0.05 ††† -0.243 **
ApoD (mg/L) 77.63 ± 13.32 59.44 ± 7.52 31.75 ± 7.59 †††
† p < 0.05, †† p < 0.01, ††† p < 0.001 compared to the GWG 11-18 kg group. Pearson correlations (r) are significant at * p < 0.05, ** p < 0.01, ***p 
< 0.001. Significant Pearson correlations are indicated in bold.
Plasma ApoD levels during pregnancy Figure 1
Plasma ApoD levels during pregnancy. ApoD levels 
were measured in women with a BMI of 20-26 kg/m2 and a 
GWG of 11-18 kg at the two first trimesters of pregnancy 
(1st and 2nd) and at delivery. ApoD levels in the venous cord 
blood were also measured. Data are expressed as means ± 
SEM. * indicates significant differences compared to the first 
trimester (p < 0.001). # indicates significant differences com-
pared to the second trimester (p < 0.001). & indicates signifi-
cant differences compared to the pregnant groups and to 
cord blood (p < 0.001).
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noticed in women with normal or low BMI but, although
not significant, this tendency was also observed in women
with high BMI (Figure 2A). Interestingly, the placental
ApoD protein content diverged from the mRNA levels and
was affected both by GWG and by BMI (Figure 2B). High
BMI with suboptimal GWG groups contained the lower
levels of ApoD whereas the higher levels of ApoD were
observed in low BMI groups having suboptimal GWG.
Low levels of ApoD were also detected in the normal BMI,
low GWG group. Nevertheless, ApoD levels were similar
in normal GWG groups, independently of BMI.
Postpartum plasma ApoD levels
Given that plasma ApoD levels were decreased by 70% at
the end of pregnancy, we examined if, in control women,
ApoD levels returned to baseline values two months after
delivery and whether these levels were affected by lacta-
tion (Figure 3). Breast-feeding (lactating) women had
plasma ApoD levels similar to non-pregnant women.
However, in bottle-feeding (non-lactating) women, ApoD
concentration remained comparable to the levels at deliv-
ery.
Discussion
To our knowledge, this study is the first to demonstrate
that plasma ApoD levels decrease during pregnancy.
Plasma ApoD levels were already significantly lower dur-
ing first trimester of pregnancy than values detected in
non-pregnant women and continued to decrease until the
end of pregnancy. The mechanisms governing this
decrease are currently unknown, but many potential rea-
sons could explain it.
As for albumin, which concentration is lowered by 30%
during pregnancy [45], the decrease in plasma ApoD lev-
els could be explained in part by hemodilution. Maternal
blood volume increases until term and although depend-
ant on many factors, the average increase in volume at
term is 45-50% [46]. Still, although it could explain the
decrease in plasma ApoD levels at the first and second tri-
mesters of pregnancy, hemodilution alone cannot explain
the observed 70% decrease of plasma ApoD at delivery.
Low levels of plasma ApoD could also result from
decreased ApoD synthesis or secretion. Plasma ApoD can
originate from many sources, one of which being the pla-
centa. Since ApoD mRNA levels are almost as high in pla-
centa as in adrenal glands and spleen, major sources of
ApoD in non-pregnant humans [9], decreased ApoD tran-
scription is unlikely the origin of low plasma ApoD con-
centration. Another argument against ApoD
transcriptional downregulation is the presence of oxida-
tive and inflammatory markers mostly in complicated but
also in normal pregnancies [47]. Oxidative stress [26-29]
and inflammation [25,26] were both reported as intensi-
fying ApoD mRNA production. ApoD decrease could also
be caused by the inhibition of its translation or the
increase of its degradation rate. More likely, the decline in
ApoD levels could be imputable to its reduced secretion
by placenta and other tissues during pregnancy. In addi-
Table 3: Population characteristics according to maternal plasma cholesterol levels at delivery and association with plasma ApoD 
levels.
LC
n = 38
HC
n = 29
Mean ± SEM r Mean ± SEM r
Mother age (years) 30.40± 0.78 0.282 *** 31.70± 0.91 -0.055
Gestational age (weeks) 39.30± 0.25 0.100 39.50± 0.23 -0.066
BMI (kg/m2) 22.68± 0.33 0.086 23.26± 0.68 0.175
GWG (kg) 14.26± 0.43 -0.321 *** 12.16± 0.47 † *** -0.054
Newborn weight (g) 3452.43± 83.90 -0.329 3389.27± 67.13 0.398 *
Newborn height (cm) 51.86± 0.39 0.114 51.77± 0.40 0.009
Cord blood ApoD (mg/L) 59.17± 13.31 -0.005 59.33± 11.57 0.490
Total cholesterol (mM) 5.95± 0.13 † -0.533 *** 9.08± 0.17 † *** 0.023
LDL-cholesterol (mM) 2.94± 0.12 † 0.314 *** 5.65± 0.18 † *** -0.040
HDL-cholesterol (mM) 1.75± 0.09 -0.215 *** 1.79± 0.10 0.063
Triglycerides (mM) 2.76± 0.18 -0.178 3.59± 0.18 † *** -0.033
Free fatty acids (mmol/L) 0.51± 0.06 -0.268 *** 0.63± 0.08 -0.310 ***
ApoA-I (g/L) 2.09± 0.06 -0.422 *** 2.24± 0.08 * 0.028
ApoB-100 (mg/L) 1.18± 0.04 † -0.413 *** 1.82± 0.04 † *** 0.071
ApoD (mg/L) 57.69± 14.16 63.05± 11.54
LC: low cholesterol; HC: high cholesterol. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the LC group. † p < 0.001 compared to the control 
group (BMI 20-26 kg/m2, GWG 11-18 kg). Pearson correlations (r) are significant at * p < 0.05, ** p < 0.01, *** p < 0.001. Significant Pearson 
correlations are indicated in bold.Reproductive Biology and Endocrinology 2009, 7:92 http://www.rbej.com/content/7/1/92
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tion, as prolonged exposure to physiological concentra-
tions of 17 beta-estradiol inhibited markedly (70-90%)
ApoD secretion in human breast cells [19], high estrogen
concentrations, as seen during gestation [48,49], could be
the root of plasma ApoD decrease.
Assuming that ApoD synthesis and degradation rates
remain unchanged, a reduced secretion will result in
ApoD accumulation inside tissues. In the placenta, in col-
laboration with other molecules, ApoD could play a key
role in the transport of essential nutrients, regulation fac-
tors and toxic metabolites between the mother and the
fetus. Those could include cholesterol [9], arachidonic
acid [13,50], steroids [11,12], vitamin A and thyroid hor-
mones [37] as well as the removal of bilirubin [10].
It was already reported that ApoD levels in newborns rep-
resent about 37% of the levels found in adults [51,52].
Accordingly, we observed that the concentration of circu-
lating ApoD in the venous cord blood was very similar to
that of the mother at delivery, which is about 30% of the
levels in non-pregnant women, although the levels found
in the cord blood and in the mother were not statistically
correlated. This lack of correlation suggests that ApoD
does not pass through the placental barrier. Since ApoD
mRNA expression occurs as early as E8.5 during mouse
embryogenesis [34], the fetus might not be dependent on
a maternal ApoD supply. Furthermore, the similarity in
mother and venous cord blood ApoD concentrations sug-
gests that even if maternal plasma ApoD does not directly
cross the placental barrier, both might be subjected to the
same regulatory mechanisms.
We also observed that, while prepregnancy maternal BMI
had no incidence on plasma ApoD concentrations on
both mother and cord blood, high GWG (> 18 kg) signif-
icantly decreased ApoD values. This decrease is very likely
multifactorial. In this particular case, it could, among oth-
ers, be related to defects in lipid metabolism. Indeed, high
GWG groups displayed lower levels of total cholesterol,
LDL-cholesterol, and ApoB-100. This was present in nor-
mal and high BMI groups but the tendency, although not
significant, was also observed in the low BMI group. This
was also observed in the group composed of all women
with high GWG regardless of their BMI. In addition, in
this group, ApoD and lipid markers were strongly corre-
lated. An involvement of ApoD in lipid metabolism was
already suggested. Because of its capacity to bind choles-
terol and its presence on lipoprotein fractions [8], ApoD,
in collaboration with ApoA-I, lecithin-cholesterol acyl-
transferase (LCAT) and cholesteryl ester transfer protein
ApoD levels in placenta according to pre-pregnancy BMI and  GWG Figure 2
ApoD levels in placenta according to pre-pregnancy 
BMI and GWG. (A) The level of apoD mRNA expression 
was measured by qRT-PCR using specific primers for apoD. 
Data are expressed as the normalized ratio of apoD mRNA 
to 18S RNA (means ± SEM). (B) The placental ApoD protein 
content was measured by ELISA. The values (means ± SEM) 
were normalized by the total protein content. * indicates sig-
nificant differences (p < 0.01) from the normal control group 
(BMI 20-26 kg/m2, GWG 11-18 kg). # indicates significant dif-
ferences (p < 0.01) from the group of similar GWG and nor-
mal BMI (20-26 kg/m2).
0
1
2
3
< 11
(n=5)
11-18
(n=5)
> 18
(n=6)
< 11
(n=5)
11-18
(n=7)
> 18
(n=6)
< 11
(n=8)
11-18
(n=6)
> 18
(n=5)
< 20 20-26 > 26
N
o
r
m
a
l
i
z
e
d
 
r
a
t
i
o
GWG
BMI
0
0,5
1,0
1,5
2,0
2,5
< 11
(n=5)
11-18
(n=5)
> 18
(n=6)
< 11
(n=5)
11-18
(n=8)
> 18
(n=5)
< 11
(n=8)
11-18
(n=6)
> 18
(n=5)
< 20 20-26 > 26
GWG
BMI
P
l
a
c
e
n
t
a
l
 
a
p
o
D
(
+
g
/
m
g
 
t
o
t
a
l
 
p
r
o
t
e
i
n
)
A
B
* * * *
* *
* #
* #
* #
The effect of breast- and bottle-feeding on plasma ApoD lev- els Figure 3
The effect of breast- and bottle-feeding on plasma 
ApoD levels. ApoD concentration was measured in moth-
ers two months after delivery (women with a BMI of 20-26 
kg/m2 and a GWG of 11-18 kg) and compared with levels at 
delivery and in non-pregnant women (BMI 20-26 kg/m2). 
Data are expressed as means ± SEM. * indicates significant 
differences compared to non-pregnant women (p < 0.001). # 
indicates significant differences compared to breast-feeding 
women (p < 0.001).
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(CETP) [53], may participate in the cholesterol transport
pathway. Furthermore, genetic variation in ApoD affects
the serum lipid levels [54].
Nevertheless, lipid levels are probably not the major fac-
tors responsible for low ApoD levels in these groups.
Indeed, high GWG groups are not the only ones present-
ing levels of total cholesterol, LDL-cholesterol, and ApoB-
100 different from the control group as well as correla-
tions between ApoD and lipid levels. In addition, the low
BMI group does not show a significant decrease of these
lipid parameters. Finally, the ApoD concentration is simi-
lar in the control, HC and LC groups, the latter showing
similarities with the high GWG groups.
Our results also suggest that a tight regulation of placental
ApoD transcription and secretion is probably involved in
the lower circulating ApoD concentrations in women with
excessive GWG. In the view that ApoD may play a key role
in the control of fetal homeostasis, the regulation of ApoD
levels becomes vital for the pregnancy outcome and the
health of the newborn. Thus, in women with high GWG,
a decrease in circulating ApoD is desirable in order to
reduce lipid transfer to fetus. This could be achieved both
by reducing the ApoD transcription and by preventing
ApoD from leaving the placenta. Consistently, high GWG
have low ApoD mRNA levels and normal or high placen-
tal ApoD content. According to this hypothesis, the lower
production of ApoD in low GWG women is disadvanta-
geous. It would then be compensated by an increased
secretion or lower degradation by the placenta and possi-
bly other tissues resulting in adequate ApoD protein con-
centration in the circulation. In overweight women (high
BMI), this control is probably altered, as evidenced by the
high ApoD mRNA and low ApoD protein levels in the pla-
centa independently of the GWG. This may explain why
the plasma ApoD levels are similar in high GWG and in
the control group. Still, plasma ApoD levels are not solely
dependent on placental regulation as high BMI groups, in
spite of high ApoD mRNA and low ApoD protein levels in
the placenta, did not show higher plasma ApoD concen-
tration than the control group. Similarly, despite low
ApoD transcript levels and high protein content in the
placenta, the low BMI, low GWG group had plasma ApoD
levels similar to the control group. This suggests that other
tissues have the ability to secrete or trap ApoD and that
they may not be subjected to the same regulatory path-
ways than the placenta.
After delivery, the return to basal, non-pregnant, plasma
ApoD levels, such as observed in breast-feeding women
was expected. However, the fact that bottle-feeding
women still have the same plasma ApoD levels than at
delivery is intriguing and suggests again that the regula-
tion of ApoD levels is complex. A possible explanation of
this discrepancy is that breast-feeding mothers have high
levels of prolactin. Prolactin was reported to exert an
antagonistic action on estrogen production in order to
maintain lactation [48,55] and could thus favor ApoD
production. In addition, breast-feeding induces the pro-
duction of cytokines [56,57], which may contribute to the
higher levels of circulating ApoD.
Conclusion
Plasma ApoD levels decrease during normal uncompli-
cated human pregnancy. ApoD is further decreased in
women with excessive GWG and their newborns. The
cause of this decrease, controlled in part at the transcrip-
tional level in the placenta, is probably multi-factorial and
may be related to pregnancy-induced changes in lipids
and hormone levels. Still, the connection between lipids,
estrogen and apoD levels is speculative and requires fur-
ther studies.
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